Laso’s endorse Maccabi their first local defeat and break their bad streak Photo: Getty Real Madrid cut its crisis of results in the Euroleague of basketball with a victory (77-81) against Maccabi on day 22, a worked triumph in the hitherto impregnable Menora Mivtachim Arena to recover the fight on the continental podium.Those of Pablo Laso pulled the return of Anthony Randolph (19 points and 7 rebounds) after a month of injury, Fabien Causeur (12), the direction of ‘Facu’ Campazo (11 points and 8 assists) and the intimidation of Walter Tavares ( 11 and 10 rebounds). After three defeats in Europe, Madrid gets 16-6 to defend their third position tied with CSKA and on the lookout for the intractable Anadolu Efes (18-3).In search of its best version and its rival trying to prevent it, Madrid’s visit to Tel Aviv left a thick first time. Without excessive brightness in attack, especially a low percentage of triples in both teams and 20 losses in total. Randolph, 13 points and 5 rebounds in the first quarter, returned eagerly at a high-speed start, with Wilbekin giving a replica in the premises. Madrid did not close its rebound and was under the break with the premiere of Amar’e Stoudamire and his first and only two points (36-28). The resumption, however, was white, with Facu attending the Causeur trays. The visiting defense also rose in level, an adjustment in which Tavares had a lot to do, which complicated the locals to find that second option and an offensive reference.Randolph added again and achieved the advantage of 10 points on the edge of the last quarter (44-54), but Maccabi did not throw in the towel finding the success of the triple. Wilbekin wanted to pull the car, also the emergence of Cohen or Acy of three, and they pressed the marker three minutes from the end (66-68), as they also tightened the defense against the fights of Ioannis Sfairopoulos in dead time.With the ball on the roof of Madrid, a steal from Thompkins, a rebound from Tavares and a triple from Campazzo to finish a round play they seemed to close the win a minute and a half from the end (67-74) but Dorsey forced two triples to one last effort of Madrid. Those from Laso lower the fumes to a Maccabi in 14-8 on the table and win on a demanding court to regain the missing confidence.DATA SHEET.–OUTCOME: MACCABI TEL AVIV, 77 – REAL MADRID, 81. (38-36, at rest).–EQUIPMENT.MACCABI: Bryant (5), Wilbekin (21), Caloiaro (2), Acy (9) and Hunter (8) – initial quintet – Acy, Reynolds (4), S. Cohen (-), Jackson (2), Avdija (7), Dorsey (9), Stoudamire (2) and Jake Cohen (8).REAL MADRID: Campazzo (11), Causeur (12), Deck (4), Randolph (19) and Tavares (11) – initial quintet–; Llull (5), Mickey (2), Rudy Fernández (-), Taylor (5), Carroll (-) and Thompkins (12).–PARTIALS: 19-21, 19-15, 11-21, 28-24.– ARBITRATORS: Lamonica, Rocha and Nikolic. Without eliminated.–PAVILION: Menora Mivtachim Arena, 10,689 spectators.
Academic scientists who ignore legal requirements to publicly report clinical trial results often have received large payments from drug companies involved in the studies, a STAT review of federal data found. (Piller, 12/17) Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million. GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth. The British company is reviving its position in HIV treatment as part of its strategy to return to earnings growth in 2016. (12/18) A generic drug maker owned by Endo International Plc has reached a $39 million settlement with the U.S. government and 47 states stemming from the unlawful labeling of multivitamins that contained fluoride. New York Attorney General Eric Schneiderman announced the settlement on Wednesday. The case stemmed from a 2013 whistleblower lawsuit filed under the False Claims Act in which the U.S. Department of Justice and state attorneys general later intervened. (Baryln and Raymond, 12/16) STAT: Do Drug-Firm Ties Affect Researchers’ Reporting Of Study Results? GlaxoSmithKline PLC has agreed to pay Bristol-Myers Squibb up to $1.5 billion to acquire the U.S. company’s pipeline of HIV drugs, a move which will bolster one of the U.K. drug makers’ strongest-performing areas. (Roland, 12/18) The Wall Street Journal: GlaxoSmithKline Buys Bristol-Myers Squibb’s HIV Assets Reuters: Endo Health To Pay $39M Over Fluoride Labeling Claims Reuters: Many Generic Drug Prices Outpace Inflation – Report The prices of many Medicaid-covered generic drugs have increased faster than inflation in recent years, according to a new report from the U.S. Department of Health and Human Services. The report, issued Thursday by HHS’s Office of Inspector General, said that if generic drugs had been treated the same way as brand-name drugs under Medicaid, states and the federal government could have gotten at least $1.4 billion in additional rebates from 2005 through 2014. (Pierson, 12/17) Reuters: GSK To Buy HIV Drugs From Bristol-Myers Squibb For Initial $350M GlaxoSmithKline To Buy HIV Drugs Pipeline From Bristol-Myers Squibb In other pharmaceutical news, generic drug maker Endo Health reaches a $39-million fluoride settlement over alleged mislabeling; a report finds the cost of Medicaid-generic drugs have risen faster than inflation; and researchers’ financial ties to the industry are explored. This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.